Literature DB >> 1978162

Binding to human jejunum of serum IgA antibody from children with coeliac disease.

S Kárpáti1, A Bürgin-Wolff, T Krieg, M Meurer, W Stolz, O Braun-Falco.   

Abstract

Jejunal histology and the presence of serum IgA antibodies (JAB) binding to human jejunum in vitro were studied in 139 children with severe malabsorptive symptoms. Among 33 children with confirmed coeliac disease (ESPGAN criteria), 13 (93%) of 14 sampled before starting on a gluten-free diet had JAB, none of 21 sampled had JAB while on a gluten-free diet of long duration, and 90% of 30 sampled during gluten challenge had JAB. 53 children had severe jejunal villous atrophy (probable coeliac disease): 71% of those younger than 2 years and 94% of those aged 2-18 years had JAB during gluten intake. JAB could not be detected in 53 disease control patients (normal jejunal histology) and in 3 coeliac disease patients with selective IgA deficiency. Simultaneous determination of antigliadin (AGA) and antiendomysium (EMA) levels, and gliadin and tissue absorption studies, showed that JAB and AGA are different, whereas JAB and EMA are probably identical. IgA JAB could be the target-organ-related autoantibodies in coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978162     DOI: 10.1016/0140-6736(90)92893-m

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease.

Authors:  S Krupicková; L Tucková; Z Flegelová; M Michalak; J R Walters; A Whelan; J Harries; J Vencovský; H Tlaskalová-Hogenová
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

2.  ACP Broadsheet No 149: September 1996. Serological diagnosis of gluten sensitive enteropathy.

Authors:  D J Unsworth
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

3.  Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies.

Authors:  A Lerner; V Kumar; T C Iancu
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

4.  Gliadin peptides activate blood monocytes from patients with celiac disease.

Authors:  Jana Cinova; Lenka Palová-Jelínková; Lesley E Smythies; Marie Cerná; Barbara Pecharová; Milos Dvorák; Pavel Fruhauf; Helena Tlaskalová-Hogenová; Phillip D Smith; Ludmila Tucková
Journal:  J Clin Immunol       Date:  2007-01-27       Impact factor: 8.317

5.  Salivary IgA antigliadin antibody as a marker for coeliac disease.

Authors:  V Hakeem; R Fifield; H F al-Bayaty; M J Aldred; D M Walker; J Williams; H R Jenkins
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

6.  Ultrastructural binding sites of endomysium antibodies from sera of patients with dermatitis herpetiformis and coeliac disease.

Authors:  S Kárpáti; M Meurer; W Stolz; A Bürgin-Wolff; O Braun-Falco; T Krieg
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

7.  IgA anti-endomysial antibodies on human umbilical cord tissue for celiac disease screening. Save both money and monkeys.

Authors:  U Volta; N Molinaro; L de Franceschi; D Fratangelo; F B Bianchi
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

8.  IgA antibodies to jejunum. Specific immunity directed against target organ of gluten-sensitive enteropathy.

Authors:  U Volta; N Molinaro; D Fratangelo; F B Bianchi
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

9.  Endomysial antibody: is it the best screening test for coeliac disease?

Authors:  M Ferreira; S L Davies; M Butler; D Scott; M Clark; P Kumar
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

Review 10.  Cutaneous manifestations in celiac disease.

Authors:  L Abenavoli; I Proietti; L Leggio; A Ferrulli; L Vonghia; R Capizzi; M Rotoli; P L Amerio; G Gasbarrini; G Addolorato
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.